Multiple Myeloma | VEOMED
Links shared publicly online about this topic.
- 1,348total visits
Multiple Myeloma | VEOMED
View full resource at veomed.com
Tags: Multiple Myeloma
Most Recently Shared on June 20, 2010 at 6:20 pm By:
Multiple Myeloma, Veomed Ppt. Team www.pbm.va.gov and www.asg.amp.edu.pl http://ow.ly/20kGW
Oncology News - Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma |3984613
mdlinx.com — “Oncology Medical Article: Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma” View full resource at mdlinx.com
Most Recently Shared on March 26, 2012 at 1:42 pm By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexame... http://t.co/j626J9jq #oncology
Multiple Myeloma: International Myeloma Foundation
myeloma.org — “Multiple Myeloma: International Myeloma Foundation” View full resource at myeloma.org
Most Recently Shared on March 26, 2012 at 1:01 pm By:
Did you know multiple #myeloma is more prevalent in the US in African Americans than Caucasians? Get informed. Visit http://t.co/RMdPpFLd
Lenalidomide Improves Outcomes in Asymptomatic High-Risk Smoldering and Newly Diagnosed Myeloma
onclive.com — “Continuous treatment with lenalidomide given early prolonged the time to progression, compared with no treatment in patients with high-risk, asymptomatic, smoldering, multiple myeloma.” View full resource at onclive.com
Most Recently Shared on March 23, 2012 at 8:48 pm By:
Early, continuous treatment with Revlimid prolonged the time to progression in patients with smoldering #myeloma http://t.co/2C5Cn060
Oncology News - Prognostic significance of serum cystatin C in multiple myeloma |3990468
mdlinx.com — “Oncology Medical Article: Prognostic significance of serum cystatin C in multiple myeloma” View full resource at mdlinx.com
Most Recently Shared on March 23, 2012 at 7:13 am By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Prognostic significance of serum cystatin C in multiple myeloma: International Journal of Hematology http://t.co/COP93FTI #oncology
Risk of subsequent primary cancer among pr... [Eur J Cancer Prev. 2012] - PubMed - NCBI
ncbi.nlm.nih.gov — “PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.” View full resource at ncbi.nlm.nih.gov
Most Recently Shared on March 22, 2012 at 8:26 pm By:
Physician Relations Health Organization
RT @Myeloma_Doc Patients with prostate cancer have increased risk of second malignancies, including multiple #myeloma http://t.co/I7MOIMdu
Open Access | VEOMED
veomed.com — “Open Access | VEOMED” View full resource at veomed.com
Most Recently Shared on March 21, 2012 at 7:40 pm By:
Browse our Open Access library for videos on multiple medical topics, search by your interest! http://t.co/vquXa5sc
Addition of Vorinostat to Bortezomib Achieves Modest Improvement in Progression-Free Survival in Relapsed/Refractory Multiple Myeloma
onclive.com — “Vorinostat added to bortezomib improved progression-free survival compared with bortezomib plus placebo in patients with relapsed/refractory multiple myeloma.” View full resource at onclive.com
Most Recently Shared on March 20, 2012 at 2:13 pm By:
Addition of Vorinostat to Bortezomib Achieves Modest Improvement in PFS for Relapsed/Refractory Multiple Myeloma http://t.co/TVDwPrdN
Multiple Myeloma - A Patient Moving Forward - Life With Multiple Myeloma
lifewithmultiplemyeloma.org — “This interview with a multiple myeloma patient is from our Living Well With Multiple Myeloma event held at SCCA in November 2011. Learn about life after a ...” View full resource at lifewithmultiplemyeloma.org
Most Recently Shared on March 19, 2012 at 9:29 pm By:
Ben Munoz - Ben's Friends Support
Multiple Myeloma - A Patient Moving Forward - Life With Multiple Myeloma http://t.co/5GPskreS #bensfriends #multiplemyeloma #cancer #support
Study: Myeloma Survival Gains, but QOL Slides : IMNG Oncology Report
oncologyreport.com — “The Oncology Report is an independent news source that provides oncologists with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice. The Oncology Report is owned by the International Medical News Group (IMNG) division of Elsevier.” View full resource at oncologyreport.com
Most Recently Shared on March 19, 2012 at 6:39 pm By:
Bob Finn - Medical News Net Health News
Patients with multiple myeloma can live longer, but their quality of life suffers, study says. http://t.co/50XpzIEw
Multiple Myeloma - Immunotherapy - Life With Multiple Myeloma
lifewithmultiplemyeloma.org — “Watch as multiple myeloma experts Dr. Bill Bensinger of Seattle Cancer Care Alliance and Dr. Noopur Raje of Masschusetts General Hospital discuss what may be...” View full resource at lifewithmultiplemyeloma.org
Most Recently Shared on March 18, 2012 at 9:34 pm By:
Ben Munoz - Ben's Friends Support
Multiple Myeloma - Immunotherapy - Life With Multiple Myeloma http://t.co/Js1bpFKT #bensfriends #myeloma #cancer #support
Oncology Medical Article | Two cycles of the PAD combination (PS-341/ Bortezomib, Adriamycin, and Dexamethasone) followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients
mdlinx.com — “Oncology Medical Article: Two cycles of the PAD combination (PS-341/ Bortezomib, Adriamycin, and Dexamethasone) followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients” View full resource at mdlinx.com
Most Recently Shared on March 15, 2012 at 8:34 am By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Two cycles of the PAD combination (PS-341/ Bortezomib, Adriamycin, and Dexamethasone) followed by auto... http://t.co/hSaf9pCo #oncology
Carfilzomib May Offer Advantages in Patients with Relapsed/Refractory Multiple Myeloma - The ASCO Post
ascopost.com — “Carfilzomib May Offer Advantages in Patients with Relapsed/Refractory Multiple Myeloma - The ASCO Post” View full resource at ascopost.com
Most Recently Shared on March 14, 2012 at 3:50 pm By:
The ASCO Post Hematology, Oncology, and Health Magazine
#Carfilzomib May Offer Advantages in Patients with Relapsed/Refractory #MultipleMyeloma http://t.co/hI6T0uSF
What are the key statistics about multiple myeloma?
cancer.org — “Multiple myeloma is a relatively uncommon cancer.” View full resource at cancer.org
Most Recently Shared on March 13, 2012 at 12:59 pm By:
ASH Health Organization and Hematology
@ACE_B_mke Hi & thx for your tweet. Check out these pages for more on #myeloma: http://t.co/a4pxXc9U & http://t.co/IqCBbiim
Oncology Medical Article | Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma
mdlinx.com — “Oncology Medical Article: Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma” View full resource at mdlinx.com
Most Recently Shared on March 13, 2012 at 9:22 am By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma... http://t.co/EUGSk1gi #oncology
Early Versus Delayed Autologous Transplantation After Immunomodulatory Agents-Based Induction Therapy in Patients With Newly Diagnosed Multiple Myeloma - OncologySTAT
oncologystat.com — “2012 Mar 1;118(6):1585-1592 - SK Kumar, MQ Lacy, A Dispenzieri, MA Gertz, et al” View full resource at oncologystat.com
Most Recently Shared on March 8, 2012 at 4:09 pm By:
OncologySTAT Oncology and Health Site
Story of the Week: Early or Delayed, Auto-SCT Delivers Comparable Survival in Myeloma http://t.co/zG2MO7aI
Advertisement
